Literature DB >> 22282905

Characteristics of oral mucosal events related to bevacizumab treatment.

Igor T Gavrilovic1, Yevgeniy Balagula, Alyx C Rosen, Vijay Ramaswamy, Maura N Dickler, Ira J Dunkel, Mario E Lacouture.   

Abstract

BACKGROUND: Bevacizumab, a monoclonal antibody targeting a vascular endothelial growth factor (VEGF) protein, has been reported to induce mucosal toxicities. However, the clinical characteristics of these particular toxicities have not been well characterized. We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab.
METHODS: A retrospective review of medical records and clinical photographs was performed with specific attention to clinical presentation, evolution, associated symptoms, concomitant medications, and treatment methods.
RESULTS: In total, four patients presented to the dermatology service with clinical findings characterized by multifocal, erythematous circinate and serpiginous erosions on the dorsal tongue surrounded by white hyperkeratotic rims that were temporally related to bevacizumab therapy. Associated increased sensitivity to spicy foods was frequently observed.
CONCLUSION: These characteristic clinical findings are consistent with geographic tongue. However, large prospective evaluations are necessary to confirm this potential relationship. If bevacizumab is indeed associated with geographic tongue, increased awareness may result in improved reporting and characterization of this particular adverse event.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22282905      PMCID: PMC3286177          DOI: 10.1634/theoncologist.2011-0198

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  20 in total

Review 1.  Toxicities of targeted therapy and their management in kidney cancer.

Authors:  Giuseppe Di Lorenzo; Camillo Porta; Joaquim Bellmunt; Cora Sternberg; Ziya Kirkali; Michael Staehler; Steven Joniau; Francesco Montorsi; Carlo Buonerba
Journal:  Eur Urol       Date:  2011-01-14       Impact factor: 20.096

Review 2.  Oral complications of targeted cancer therapies: a narrative literature review.

Authors:  A L Watters; J B Epstein; M Agulnik
Journal:  Oral Oncol       Date:  2011-04-22       Impact factor: 5.337

Review 3.  Benign migratory glossitis or geographic tongue: an enigmatic oral lesion.

Authors:  Dimitrios Assimakopoulos; George Patrikakos; Christina Fotika; Moses Elisaf
Journal:  Am J Med       Date:  2002-12-15       Impact factor: 4.965

4.  Prevalence of fissured tongue, geographic tongue and median rhomboid glossitis among Israeli adults of different ethnic origins.

Authors:  Noam Yarom; Uri Cantony; Meir Gorsky
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

Review 5.  Adverse effects of anticancer agents that target the VEGF pathway.

Authors:  Helen X Chen; Jessica N Cleck
Journal:  Nat Rev Clin Oncol       Date:  2009-07-07       Impact factor: 66.675

6.  [A retrospective study of oral adverse events with colorectal cancer chemotherapy using bevacizumab].

Authors:  Hiroko Takahashi; Miyuki Sato; Kou Tsukada; Setsuo Tsuchiya; Shigeru Tanda
Journal:  Gan To Kagaku Ryoho       Date:  2011-06

Review 7.  Common tongue conditions in primary care.

Authors:  Brian V Reamy; Richard Derby; Christopher W Bunt
Journal:  Am Fam Physician       Date:  2010-03-01       Impact factor: 3.292

8.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

9.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

Authors:  Martin H Cohen; Yuan Li Shen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2009-11-06

Review 10.  Bevacizumab (Avastin).

Authors:  S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-24       Impact factor: 3.825

View more
  5 in total

1.  Geographical tongue induced by axitinib.

Authors:  Santhanam Sundar; Frances Burge
Journal:  BMJ Case Rep       Date:  2015-10-16

Review 2.  Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.

Authors:  Viswanath Reddy Belum; Andrea Cercek; Virginia Sanz-Motilva; Mario E Lacouture
Journal:  Curr Treat Options Oncol       Date:  2013-09

3.  Geographic tongue induced by angiogenesis inhibitors.

Authors:  Thomas Hubiche; Bruno Valenza; Christine Chevreau; Jean-Christophe Fricain; Pascal Del Giudice; Vincent Sibaud
Journal:  Oncologist       Date:  2013-04-10

4.  Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma.

Authors:  Shokoufeh Shahrabi-Farahani; Marina Gallottini; Fabiana Martins; Erik Li; Dayna R Mudge; Hironao Nakayama; Kyoko Hida; Dipak Panigrahy; Patricia A D'Amore; Diane R Bielenberg
Journal:  Am J Pathol       Date:  2016-02-11       Impact factor: 4.307

Review 5.  Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.

Authors:  Emmanuelle Vigarios; Joel B Epstein; Vincent Sibaud
Journal:  Support Care Cancer       Date:  2017-02-22       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.